CAR-T Meeting 2023 – VJRegenMed

Multivalent gamma-delta T-cells: promising agents for the treatment of cancers

Anya Kerkache — Wed, 08 Mar 2023 10:35:19 +0000

In this video, Jürgen Kuball, MD, PhD, Utrecht University, Utrecht, The Netherlands, briefly discusses the promise of novel gamma delta T-cells, which are being explored for the treatment of various cancers and have shown promising pre-clinical results. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

CAR-T therapy in acute and chronic leukemias: current applications and future outlooks

Anya Kerkache — Wed, 08 Mar 2023 10:35:19 +0000

John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, shares some insights into clinical indications for CAR-T therapy in acute and chronic leukemias, highlighting recent updates and challenges in this space. Prof. Gribben first discusses the role of CAR-T therapy in acute lymphoblastic leukemia (ALL), drawing focus on the two approved products in this malignancy. Prof. Gribben then goes on to explain mechanisms of resistance to CAR-T therapy in ALL, and ongoing research in this space. Following this, Prof. Gribben discusses updates and challenges with the use of CAR-T therapy in T-cell malignancies and acute myeloid leukemia (AML), and concludes by highlighting challenges with developing efficacious CAR-T products for chronic lymphocytic leukemia (CLL), which may be overcome by combining CAR-T cells with Bruton’s tyrosine kinase (BTK) inhibitors. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Novel CAR-T constructs emerging for patients with multiple myeloma who experience loss of BCMA

Anya Kerkache — Wed, 08 Mar 2023 10:35:19 +0000

Hermann Einsele, MD, FRCP, University Hospital of Würzburg, Würzburg, Germany, briefly discusses CAR-T constructs emerging for patients with multiple myeloma who experience loss of BCMA, including agents targeting GPRC5D, CD38 and SLAMF7. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Exploring the potential role of CD7-targeting CAR-T cells in T-ALL

Anya Kerkache — Wed, 08 Mar 2023 10:35:18 +0000

Maksim Mamonkin, PhD, Baylor College of Medicine, Houston, TX, shares some insights into the promise of CD7-targeting CAR-T therapies for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL). Dr Mamonkin explains methods used to develop these products, and further highlights the promising activity that has been observed in ongoing clinical trials. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

The importance of managing hematologic toxicity associated with CAR-T therapy

Anya Kerkache — Wed, 08 Mar 2023 10:35:17 +0000

In this video, Marion Subklewe, MD, Ludwig-Maximilians University of Munich, Munich, Germany, comments on the importance of improving methods of assessing and managing hematologic toxicity associated with the use of CAR-T therapy. Prof. Subklewe also shares some insights into the novel CAR-HEMATOTOX risk stratification tool being evaluated in patients treated with CAR-T therapy for various hematological malignancies. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Challenges with CAR-T therapy in AML & insights into IF-BETTER-gated CAR-T cells

Anya Kerkache — Wed, 08 Mar 2023 10:35:16 +0000

Sascha Haubner, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses challenges with developing efficacious CAR-T cell products for the treatment of patients with acute myeloid leukemia (AML), highlighting the heterogeneity of this disease. Dr Haubner then shares some insights into the development of IF-BETTER-gated CAR-T cells, which have demonstrated promising pre-clinical activity and will soon be evaluated in a first-in-human trial. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Rapid CAR-T manufacturing and challenges in this space

Anya Kerkache — Wed, 08 Mar 2023 10:35:16 +0000

Nina Worel, MD, Medical University of Vienna, Vienna, Austria, shares some insights into challenges with CAR-T manufacturing, explaining that even rapid manufacturing processes may require patients to wait up to four weeks before they can receive treatment. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

An insight into novel third-generation TLR2 co-stimulatory CAR-T cells

Anya Kerkache — Wed, 08 Mar 2023 10:35:15 +0000

In this video, Yasmin Nouri, BSc, MSc, Malaghan Institute of Medical Research, Wellington, New Zealand, shares some insights into the development of a novel third-generation TLR2 co-stimulatory CAR-T cell product for the treatment of B-cell malignancies, which has demonstrated promising activity in a Phase I clinical trial. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.